Saturday 17 October 2026
Export ISPC’s income statement to Excel — free account
iSpecimen Inc.
ISPC Healthcare Diagnostics & Research
iSpecimen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 million, down 79.2% from fiscal 2024. In the quarter to June 2026, revenue fell 78.7%, EPS grew 94.2% and free cash flow fell 257.7%, each against the same quarter a year earlier.
0.92
0.11
−10.68%
Follow ISPC
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
7.92 | 2.09 | 0.62 | 2.25 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(5.36) | (0.64) | (1.31) | (3.70) | |
P/B ratio |
2.13 | 2.63 | 0.39 | 2.45 | |
Price to Tangible BV |
5.02 | 0.00 | 0.57 | 3.01 | |
EV/Sales |
4.06 | 1.89 | (1.59) | 2.20 | |
EV/EBITDA |
0.00 | 0.00 | 0.42 | 0.00 | |
EV/Operating CF |
(0.27) | (0.30) | 0.72 | (1.07) | |
EV/FCF |
(0.17) | (0.19) | 0.41 | (0.72) | |
Quick Ratio |
0.81 | 0.53 | 1.11 | 0.51 | |
Current Ratio |
0.82 | 0.62 | 1.12 | 0.63 | |
Net Debt/EBITDA |
3.80 | 1.17 | 3.02 | 1.17 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.07 | 0.15 | 0.20 | 0.33 | |
Operating CF/Net income |
0.51 | 1.48 | 0.18 | 0.73 | |
Capex/Depreciation |
0.00 | (5.15) | 0.00 | (2.18) | |
Research and Development Expense of Revenue |
24.69% | 21.79% | 61.39% | 21.01% | |
Selling, General and Administrative Expense of Revenue |
649.77% | 1,424.81% | 2,799.61% | 1,880.86% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.10 | 0.06 | |
Share Based Compensation of Revenue |
0.13% | 0.64% | 3.47% | 1.69% | |
Graham Net Nets |
(0.32) | (1.08) | 0.43 | (0.31) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(2,129.81%) | (1,150.64%) | (903.85%) | (611.63%) | |
Free Cash Flow Yield |
(293.81%) | (483.07%) | (623.53%) | (136.38%) | |
Revenue per Share |
0.11 | 0.46 | 0.45 | 0.73 | |
Operating CF per Share |
(0.49) | (9.85) | (7.97) | (13.94) | |
Capex per Share |
0.00 | (2.05) | 0.00 | (6.85) | |
Free Cash Flow per Share |
(0.49) | (11.90) | (7.97) | (20.79) | |
Cash per Share |
3.17 | 8.26 | 59.78 | 19.06 | |
Shareholders Equity per Share |
1.25 | 2.38 | 26.83 | 21.05 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.25 | 2.38 | 26.83 | 21.05 | |
Free Cash Flow |
(0.69) | (4.06) | (0.92) | (3.04) | |
Working Capital |
(0.99) | (2.12) | 0.72 | (2.10) | |
Capital Expenditures |
0.00 | (0.70) | 0.00 | (1.00) | |
Net Current Asset Value |
(1.17) | (2.31) | 0.51 | (2.32) | |
EV/EBIT |
0.00 | 0.00 | 0.34 | 0.00 | |
Capex to Sales |
0.00 | 4.49 | 0.00 | 9.38 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.20 | 0.36 | 0.75 | 1.37 | |
Average Payables |
4.49 | 4.25 | 4.78 | 4.41 | |
Average Assets |
6.71 | 6.73 | 9.44 | 10.13 | |
Average Common Equity |
1.18 | 1.24 | 3.20 | 3.89 |
Columns are period end dates